Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Personality Disorders: Dependent and Obsessive-Compulsive01:24

Personality Disorders: Dependent and Obsessive-Compulsive

Dependent personality disorder and obsessive-compulsive personality disorder are two separate psychological conditions that influence behavior, relationships, and overall life functioning. Though both involve maladaptive behaviors, their core characteristics and motivations differ significantly.
 Dependent Personality Disorder
Dependent personality disorder is characterized by an excessive reliance on others to manage various aspects of life. Individuals with this disorder often struggle with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synucleinopathy-like clinical features and biologically defined synuclein seeding in PSP-Parkinsonism: an imperfect match.

NPJ Parkinson's disease·2026
Same author

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

NPJ Parkinson's disease·2026
Same author

Expanding PPMI through Remote Data Acquisition and Analysis: Early Success and Future Growth with myPPMI.

Annals of neurology·2026
Same author

Recruitment Strategies across the Spectrum of Neuronal Synuclein Disease.

Annals of neurology·2026
Same author

Biologic Frameworks for Synucleinopathies: Contributions of the Parkinson's Progression Markers Initiative.

Annals of neurology·2026
Same author

Analytical agreement and platform-specific decision thresholds for plasma p-tau217 measured on Lumipulse G600II and Cobas e801 in a paired CSF-plasma cohort.

Clinical chemistry and laboratory medicine·2026

Related Experiment Video

Updated: May 26, 2026

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
09:12

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

Impulse control disorders in Parkinson's disease.

Dolores Vilas1, Claustre Pont-Sunyer, Eduardo Tolosa

  • 1Institut Clínic de Neurodències, Hospital Clínic de Barcelona, Department of Medicine, Universitat de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain.

Parkinsonism & Related Disorders
|December 15, 2011
PubMed
Summary

Impulse control disorders (ICDs) affect Parkinson's disease (PD) patients more than the general population, often linked to dopamine agonist treatment. Management requires adjusting PD medications and considering alternative therapies.

More Related Videos

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Related Experiment Videos

Last Updated: May 26, 2026

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
09:12

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Area of Science:

  • Neurology
  • Psychiatry
  • Pharmacology

Background:

  • Impulse control disorders (ICDs) are more prevalent in Parkinson's disease (PD) patients, manifesting as gambling, hypersexuality, and compulsive behaviors.
  • These behavioral addictions significantly impair daily life and affect patient and family quality of life.
  • ICDs are often under-reported and under-recognized in PD, complicating patient care.

Purpose of the Study:

  • To review the prevalence, risk factors, and management strategies for impulse control disorders in Parkinson's disease.
  • To highlight the association between dopamine agonist therapy and the development of ICDs.
  • To discuss the complexities in managing ICDs within the context of PD treatment.

Main Methods:

  • Literature review of studies on impulse control disorders in Parkinson's disease.
  • Analysis of the role of dopaminergic medications, particularly dopamine agonists, in ICD development.
  • Examination of current and potential therapeutic interventions for ICDs in PD patients.

Main Results:

  • Dopamine agonists are the primary risk factor for ICDs in PD, likely due to mesolimbic D3 receptor stimulation.
  • Levodopa can also induce ICDs, but with significantly lower frequency compared to dopamine agonists.
  • Over a quarter of PD patients with ICDs exhibit multiple behavioral addictions.

Conclusions:

  • Management of ICDs in PD is challenging and often necessitates adjustments to dopaminergic therapy.
  • Alternative treatments like atypical antipsychotics, antidepressants, or deep brain stimulation may be required.
  • Early recognition and proactive management are crucial for improving outcomes in PD patients with ICDs.